• 1
    Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 2229.
  • 2
    Lundgren JD, Mocroft A. The impact of antiretroviral therapy on AIDS and survival. J HIV Ther 2006; 2: 3638.
  • 3
    Mocroft A, Phillips AN, Lundgren JD. HIV survival benefit associated with earlier antiviral therapy. Ann Intern Med 2004; 140: 578579.
  • 4
    CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell cell count and viral load in antiretroviral drug-naïve individuals and in those treated in the monotherapy era. AIDS 2004; 18: 5158.
  • 5
    Egger M, May M, Chene G et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119129.
  • 6
    Lau B, Gange S, Moore RD. Risk of non-AIDS related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4 cell+counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007; 44: 179187.
  • 7
    Weber R, Sabin CA, Friis-Møller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 16321641.
  • 8
    Smit C, Geskus R, Walker S et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20: 741749.
  • 9
    Palella FJ Jr., Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era. Changing causes of death and disease in the HIV outpatient study. J Acquir Immun Defic Syndr 2006; 43: 2734.
  • 10
    Baker JV, Peng G, Rapkin J et al. CD4 cell+count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22: 841848.
  • 11
    D:A:D Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus. Arch Intern Med 2006; 166: 16321641.
  • 12
    Monforte A, Abrams D, Pradier C et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22: 21432153.
  • 13
    El-Sadr WM, Lundgren JD, Neaton JD et al. for the Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 14
    Emery S, Neuhaus JA, Phillips AN et al. for the Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART Study. J Infect Dis 2008; 197: 11331144.
  • 15
    Crum NF, Riffenburgh RH, Wegner S et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194200.
  • 16
    Mocroft A, Brettle R, Kirk O et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 16631671.
  • 17
    Baker JV, Peng G, Rapkin J et al. Poor initial CD4 cell+recovery with antiretroviral therapy prolongs immune depletion and increases risk of AIDS and non-AIDS diseases. JAIDS 2008; 48: 541546.
  • 18
    Bautista-Arredondo S, Gadsden P, Harris JE, Bertozzi SM. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework. AIDS 2008; 22 (Suppl. 1): S67S74.
  • 19
    Joint United Nations Programme on HIV/AIDS (UNAIDS). Treatment and care: unprecedented progress, remaining challenges. Report on the global AIDS epidemic, 2008: 129159.
  • 20
    Chequer P, Cuchi P, Mazin R, García Calleja JM. Access to antiretroviral treatment in Latin American countries and the Caribbean. AIDS 2002; 16 (Suppl. 3): S50S57.
  • 21
    Bastos FI, Cáceres C, Galvao J, Veras MA, Castilho EA. AIDS in Latin America: assessing the current status of the epidemic and the ongoing response. Int J Epidemiol 2008; 37: 729737.
  • 22
    Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd ed. Philadelphia, PA, USA: Lippincott, Williams & Wilkins, 2008.
  • 23
    Robins J, Gail MG, Lubin JH. More on ‘biased selection of controls for case–control analysis of cohort studies’. Biometrics 1986; 42: 293299.
  • 24
    Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case–control studies estimate? Survey of methods and assumptions in published case–control research. Am J Epidemiol 2008; 168: 10731081.
  • 25
    McQueen MJ, Hawken S, Wang X et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet 2008; 372: 224233.
  • 26
    Kuller LH, Tracy R, Belloso WH et al. Inflammation and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
  • 27
    Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007; 31: 632643.
  • 28
    Mehta N, Reilly M. Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. HIV Clin Trials 2005; 6: 524.
  • 29
    Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257262.
  • 30
    D:A:D Study Group . Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 14171426.
  • 31
    Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 19791991.
  • 32
    Bottecchia M, Garcia-Samaniego J, Soriano V. The implications of antiviral drugs with activity against hepatitis B virus and HIV. Curr Opin Infect Dis 2007; 20: 621628.
  • 33
    Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44 (Suppl.): S65S70.
  • 34
    DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 17231735.
  • 35
    Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell cell count and HAART use status. Clin Infect Dis 2008; 47: 11021104.
  • 36
    Crabtree-Ramirez B, Gómez Palacio M, Rodríguez Rivera V, Reyes-Terán G. Baseline characteristics of HIV-infected patients attending a National Institute of Health in Mexico City: evidence of late detection of HIV infection and the urgent need for efficient. Voluntary Counseling and Testing (VCT) programs. XVII International AIDS Conference. Mexico DF, Mexico, August 2008. [Abstract THPE0244].